Evidence map›Paper›PMID 37304161›Full record

ArticlePleura and peritoneum2023

Enhanced recovery after surgery in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: national survey of peri-operative practice by Indian society of peritoneal surface malignancies.

Sampige Prasanna Somashekhar, Suryanarayana Deo, Subramanyeshwar Rao Thammineedi, Harit Chaturvedi, Ganesh Mandakukutur Subramanya, Rama Joshi, Jagdish Kothari, Ayyappan Srinivasan, Kumar C Rohit, Mukurdipi Ray and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Pleura and peritoneum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Sampige Prasanna SomashekharAster International Institute of Oncology , Aster hospital , Bengaluru, India.
Suryanarayana DeoDepartment of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Subramanyeshwar Rao ThammineediSurgical Oncology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India.
Harit ChaturvediMax Institute of Cancer care, New Delhi, India.
Ganesh Mandakukutur SubramanyaVydehi Institute of Medical Sciences and Research Centre, Bengaluru, India.
Rama JoshiGynaecological Oncology, Fortis Memorial Research Institute, Gurgaon, New Delhi, India.
Jagdish KothariHCG Cancer Centre Ahmedabad, Ahmedabad, India.
Ayyappan SrinivasanApollo Hospitals, Chennai, India.
Kumar C RohitAster International Institute of Oncology , Aster hospital , Bengaluru, India.
Mukurdipi RayDepartment of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Bharat PrajapatiHCG Cancer Centre Ahmedabad, Ahmedabad, India.
Hemanth Guddahatty NanjappaVydehi Institute of Medical Sciences and Research Centre, Bengaluru, India.
Rajagopalan RamalingamSurgical Oncology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India.
Aaron FernandesAster International Institute of Oncology , Aster hospital , Bengaluru, India.
Kyatsandra Rajagopal AshwinAster International Institute of Oncology , Aster hospital , Bengaluru, India.
Aster Medcity · INAll India Institute of Medical Sciences · INHCG Cancer Centre · INInstitute of Medical Sciences · INApollo Hospitals · INBasavatarakam Indo American Cancer Hospital and Research Institute · INCancer Hospital and Research Institute · INFortis Memorial Research Institute · INMax Healthcare · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The Enhanced recovery after surgery (ERAS) program is designed to achieve faster recovery by maintaining pre-operative organ function and reducing stress response following surgery. A two part ERAS guidelines specific for Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) was recently published with intent of extending the benefit to patients with peritoneal surface malignancies. This survey was performed to examine clinicians' knowledge, practice and obstacles about ERAS implementation in patients undergoing CRS and HIPEC. Methods: Requests to participate in survey of ERAS practices were sent to 238 members of Indian Society of Peritoneal Surface malignancies (ISPSM) via email. They were requested to answer a 37-item questionnaire on elements of preoperative (n=7), intraoperative (n=10) and postoperative (n=11) practices. It also queried demographic information and individual attitudes to ERAS. Results: Data from 164 respondents were analysed. 27.4 % were aware of the formal ERAS protocol for CRS and HIPEC. 88.4 % of respondents reported implementing ERAS practices for CRS and HIPEC either, completely (20.7 %) or partially (67.7 %). The adherence to the protocol among the respondents were as follows: pre operative (55.5-97.6 %), intra operative (32.6-84.8 %) and post operative (25.6-89 %). While most respondents considered implementation of ERAS for CRS and HIPEC in the present format, 34.1 % felt certain aspects of perioperative practice have potential for improvement. The main barriers to implementation were difficulty in adhering to all elements (65.2 %), insufficient evidence to apply in clinical practice (32.4 %), safety concerns (50.6 %) and administrative issues (47.6 %). Conclusions: Majority agreed the implementation of ERAS guidelines is beneficial but are followed by HIPEC centres partially. Efforts are required to overcome barriers like improving certain aspects of perioperative practice to increase the adherence, confirming the benefit and safety of protocol with level I evidence and solving administrative issues by setting up dedicated multi-disciplinary ERAS teams.

Indexed as

cytoreductive surgery (CRS)enhanced recovery after surgery (ERAS)hyperthermic intraperitoneal chemotherapy (HIPEC)peritoneal surface malignancy (PSM)

Identifiers

PMID37304161
PMCPMC10249752
OpenAlexW4377293237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.